3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
3
Sarcoma
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Plasma Cell
1
Desmoid Tumors
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
13
Radiosurgery
9
spartalizumab
7
lenvatinib
7
Oxaliplatin
6
Gemcitabine
5
Fluorouracil
5
Radiotherapy
4
Cisplatin
4
Bevacizumab
4
atezolizumab
3
Leucovorin
3
Folfox protocol
3
Doxorubicin
3
gadolinium ethoxybenzyl DTPA
2
fludarabine
2
cabozantinib
2
Nivolumab
2
Mitomycin
2
Electroporation
2
Cyclophosphamide
2
Chemoembolization, Therapeutic
2
tremelimumab
1
toripalimab
1
tocilizumab
1
tislelizumab
1
temsirolimus
1
tazemetostat
1
sitravatinib
1
pirarubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Carcinoma, Hepatocellular
×
liposomal doxorubicin
×
Clear all
NCT02527772
2019-06-04
LD-FOX4/HCC
Guangxi Medical University
Phase 2/3
Withdrawn